1. Die elektromechanische Entkoppelung der glatten Gefassmuskulatur als Grundprinzip der Coronardilatation durch 4-(2'Nitrophenyl)-2,6-dimethyl-1, 4-dihydropyridin-3, 5-dicarbonsaure-dimethylester (BAY a 1040 Nifedipine);Grun, G.; Fleckenstein, A.;Arzneim Forsch,1972
2. Zur Pharmakologie von 4-(2'-Nitrophenyl)-2, 6-dimethylcontinued until the performance figures had fallen 1, 4-dihydropyridin-3, 5-dicarbonsauredimethylester from the maximum values to near baseline values. (Nifedipine), BAY a 1040. Arzneim Forsch 1971; 22: None of our patients receiving nifedipine was able to exercise for more than two periods after their peak values because of fatigue, and only one of them, our poorest responder (case 12), had performance figures approaching base times. The last exercises were performed between 83 and 184 minutes after treatment (Table 4). Our results suggest, however;Vater, W.; Kroneberg, G.; Hoffmeister, F.
3. Myocardial circulation under Adalat in different phases of coronary diseases;Heeger, H.; Kahn, P.; Aldor, E.,1975
4. Adalat and beta blockers; the mechanism studied with two series of work tests in two groups of patients with angina pectoris;Ekelund, L.G.; Atterhog, J.H.,1975
5. Division of Medical Sciences Drug Efficacy Study. Final Report to the Commissioner of Food and Drugs, Food and Drug Administration;National Research Council;Washington DC: National Academy of Sciences